| | 1297538-32-9 Basic information More.. |
| Product Name: | ODM-201 | | Synonyms: | ODM-201;N-[(1S)-2-[3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide;N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide;Darolutamide (ODM-201);ODM-201(BAY-1841788);CS-1565;ODM-201(Darolutamide);N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl}-5-[(1RS)-1-hydroxyethyl]-1H-pyrazole-3-carboxamide | | CAS: | 1297538-32-9 | | MF: | C19H19ClN6O2 | | MW: | 398.85 | | EINECS: | 829-313-8 | | Mol File: | 1297538-32-9.mol |  |
Use
Moilanen, Anu Maarit, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep 5.2(2015):12007.
Fizazi, Karim, et al. ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data. Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of 2013.
Fizazi, K, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncology 5.9(2014):975-85.
- ODM-201
-
- US $1000.00-400.00 / kg
- 2024-08-16
- CAS:1297538-32-9
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 5000
- ODM-201
-
- US $40.00-35.00 / Gram
- 2024-08-06
- CAS:1297538-32-9
- Min. Order: 1Gram
- Purity: 99.99%
- Supply Ability: 50Tons
- ODM-201
-
- US $9.00-70.00 / g
- 2024-05-11
- CAS:1297538-32-9
- Min. Order: 10g
- Purity: 99%
- Supply Ability: 10 tons
|
|
1297538-32-9
Recommend Suppliers |
|